You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis
|
|---|---|
| Published in |
BMC Cancer, May 2017
|
| DOI | 10.1186/s12885-017-3323-4 |
| Pubmed ID | |
| Authors |
Francesca De Felice, Ilaria Benevento, Anna Lisa Magnante, Daniela Musio, Nadia Bulzonetti, Rossella Caiazzo, Vincenzo Tombolini |
| Abstract |
Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the role of OXP in this patient population. Literature searches were carried out in PubMed, Medline and Scopus databases. End points were overall survival (OS), disease free survival (DFS), local failure (LF) and distant failure (DF). Odd ratio (OR) with 95% confidence interval (CI) was calculated using random effects model. Four randomized trials were included. Patients treated with OXP-5FU CRT had significantly decreased DF (OR = 0.76; 95% CI, 0.60 to 0.97; p = 0.03) compared to standard CRT. OS, DFS and LF were not significantly different between groups. OXP significantly decreased DF, but does not improve OS e DFS compared to 5FU CRT. Precise role of OXP in neoadjuvant setting of LARC remains to be determined. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 5 | 16% |
| Other | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Researcher | 4 | 13% |
| Student > Master | 3 | 9% |
| Other | 7 | 22% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 59% |
| Nursing and Health Professions | 2 | 6% |
| Arts and Humanities | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2017.
All research outputs
#18,968,282
of 23,509,982 outputs
Outputs from BMC Cancer
#5,554
of 8,500 outputs
Outputs of similar age
#237,881
of 311,246 outputs
Outputs of similar age from BMC Cancer
#83
of 138 outputs
Altmetric has tracked 23,509,982 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,500 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,246 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.